A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

July 30, 2018

Primary Completion Date

September 30, 2020

Study Completion Date

April 28, 2023

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Tislelizumab

Administered intravenously as described

DRUG

Paclitaxel

Administered intravenously as described

DRUG

Nab-paclitaxel

Administered intravenously as described

DRUG

Carboplatin

Administered intravenously as described

Trial Locations (43)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100142

Beijing Cancer Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

100853

Chinese Pla General Hospital, Beijing

101149

Beijing Chest Hospital, Capital Medical University, Beijing

110042

Liaoning Cancer Hospital and Institute, Shenyang

130021

The First Hospital of Jilin University, Changchun

150000

Harbin Medical University Cancer Hospital, Harbin

200030

Shanghai Chest Hospital, Shanghai

210002

General Hospital of Eastern Theater Command, Nanjing

215006

The First Affiliated Hospital of Soochow University, Suzhou

221000

Xuzhou Central Hospital, Xuzhou

230000

Anhui Provincial Hospital, Hefei

The First Affiliated Hospital of Anhui Medical University, Hefei

250000

Qilu Hospital of Shandong University, Jinan

250013

Jinan Central Hospital, Jinan

250031

Jinan Military General Hospital, Jinan

250117

Shandong Cancer Hospital, Jinan

261000

Weifang Peoples Hospital, Weifang

300052

Tianjin Medical University General Hospital, Tianjin

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

310006

Hangzhou First Peoples Hospital, Hangzhou

310016

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

350014

Fujian Cancer Hospital, Fuzhou

361003

The First Affiliated Hospital of Xiamen University, Xiamen

400010

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

400038

Southwest Hospital, Chongqing

400042

Daping Hospital, Third Military Medical University, Chongqing

404000

Chongqing Three Gorges Central Hospital, Chongqing

410011

The Second Xiangya Hospital of Central South University, Changsha

410013

Hunan Cancer Hospital, Changsha

430022

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

430079

Hubei Cancer Hospital, Wuhan

450000

Henan Cancer Hospital, Zhengzhou

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510515

Nanfang Hospital of Southern Medical University, Guangzhou

515031

Cancer Hospital of Shantou University Medical College, Shantou

530021

The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning

563000

The Affiliated Hospital of Zunyi Medical College, Zunyi

610041

West China Hospital, Sichuan University, Chengdu

710061

The First Affiliated Hospital of Xian Jiaotong University, Xi'an

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT03594747 - A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer | Biotech Hunter | Biotech Hunter